Evidence map›Paper›PMID 33969281›Full record

ArticleiScience2021

Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients.

Connor J Dwyer, Colleen A Cloud, Cindy Wang, Philip Heidt, Paramita Chakraborty, Tara F Duke, Shannon McGue, Braxton Jeffcoat, Jaclyn Dunne, Logan Johnson and 17 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 1 institution in 1 country.

Connor J DwyerDepartment of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Colleen A CloudDepartment of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Cindy WangDepartment of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Philip HeidtDepartment of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Paramita ChakrabortyDepartment of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Tara F DukeDepartment of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Shannon McGueDepartment of Medicine, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Braxton JeffcoatDepartment of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Jaclyn DunneDepartment of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Logan JohnsonDepartment of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Seungho ChoiDepartment of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Georges J NahhasDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Amy S GandyClinical and Translational Research Center,Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Nikolina BabicLaboratory and Pathology Medicine, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Frederick S NolteLaboratory and Pathology Medicine, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Philip HoweBiochemistry and Molecular Biology, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Besim OgretmenBiochemistry and Molecular Biology, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Vamsi K GangarajuBiochemistry and Molecular Biology, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Stephen TomlinsonMicrobiology & Immunology, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Brian MaddenThe Blood Connection, 1099 Bracken Road, Piedmont, SC 29673, USA.
Tracy BridgesThe Blood Connection, 1099 Bracken Road, Piedmont, SC 29673, USA.
Patrick A FlumeDepartment of Medicine, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
John WrangleDepartment of Medicine, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Mark P RubinsteinDepartment of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Prabhakar K BaligaDepartment of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Satish N NadigDepartment of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Shikhar MehrotraDepartment of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.
Medical University of South Carolina · US

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Jian Ouyang · 2009 to 2026
$42.7M
South Carolina Clinical & Translational Research Institute (SCTR)UL1TR001450 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T., FLUME, PATRICK A · 2015 to 2024
$41.1M
Project 3: Targeting SK2/S1P Signaling for the Regulation of c-Myc and Tumor SuppressionP01CA203628 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRITTEN, CAROLYN D · 2016 to 2021
$8.9M
Anti-oxidant and Metabolic Phenotype in Regulating Tumor Specific T cell Memory ResponseR01CA236379 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MEHROTRA, SHIKHAR · 2020 to 2024
$2.5M
Understanding Metabolic and Epigenetic Cross‐ talk in Potent Anti‐ tumor T cellsR01CA250458 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MEHROTRA, SHIKHAR · 2020 to 2024
$2.3M
Intersections of RNA-binding proteins and T-cells in oral epithelial plasticityR01DE030013 · NIDCR · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI MEHROTRA, SHIKHAR, PALANISAMY, VISWANATHAN · 2020 to 2024
$2.3M
Lymphocyte and inflammatory cytokine markers of response in the first-in-human combination of anti-PD-1 mAb and IL-15/IL-15Ra complexes and investigation of mediators of anti-tumor immune responsesR01CA222817 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RUBINSTEIN, MARK P, WRANGLE, JOHN M. · 2019 to 2023
$2.0M
Oxidative stress and AICD in memory T cell persistenceR01CA138930 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MEHROTRA, SHIKHAR · 2010 to 2014
$1.5M
Programming Metabolically Fit TILs for ImmunotherapyR41CA239952 · NCI · LIPO-IMMUNO TECH, LLC · PI MEHROTRA, SHIKHAR · 2020 to 2020
$225k
NCATS NIH HHS UL1 TR001450NCI NIH HHS P01 CA203628NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA138930NCI NIH HHS R01 CA222817NCI NIH HHS R01 CA236379NCI NIH HHS R01 CA250458NCI NIH HHS R41 CA239952NIDCR NIH HHS R01 DE030013
6 · The paper itself

Abstract

The SARS-CoV-2 viral pandemic has induced a global health crisis, which requires more in-depth investigation into immunological responses to develop effective treatments and vaccines. To understand protective immunity against COVID-19, we screened over 60,000 asymptomatic individuals in the Southeastern United States for IgG antibody positivity against the viral Spike protein, and approximately 3% were positive. Of these 3%, individuals with the highest anti-S or anti-RBD IgG level showed a strong correlation with inhibition of ACE2 binding and cross-reactivity against non-SARS-CoV-2 coronavirus S-proteins. We also analyzed samples from 94 SARS-CoV-2 patients and compared them with those of asymptomatic individuals. SARS-CoV-2 symptomatic patients had decreased antibody responses, ACE2 binding inhibition, and antibody cross-reactivity. Our study shows that healthy individuals can mount robust immune responses against SARS-CoV-2 without symptoms. Furthermore, IgG antibody responses against S and RBD may correlate with high inhibition of ACE2 binding in individuals tested for SARS-CoV-2 infection or post vaccination.

Indexed as

ImmunologyInfection control in health technologyVirology

Identifiers

PMID33969281
PMCPMC8087581
OpenAlexW3158056827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.